Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.6452W HIGH $104.00
Volume
2.41 M
Value Traded
23.48 M
Short % Float
16.31%
-13.97%Week
+145.8%1 Month
+96.58%3 Month
+100.67%6 Month
-55.74%5 Year
+262.3%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.10 B
EPS (TTM)
-3.85
P/E Ratio
-
Ent. Value
4.97 B
Total Shares
62.85 M
Float Shares
57.48 M
Insiders
8.55%
Institutions
102.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KOD Catalyst Timeline
Dated clinical, regulatory and corporate events for Kodiak Sciences Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kodiak Sciences Inc
440Total events
12Upcoming
73Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationZenkudaPresentation
Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy presented at AAO 2026
diabetic retinopathysource ↗
◆Oral PresentationZenkudaPresentation
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted at AAO 2026 Retina Subspecialty Day
wet age-related macular degenerationsource ↗
◆Oral PresentationKSI-101Presentation
Phase 1b APEX data for KSI-101 in MESI presented at AAO 2026 Uveitis Subspecialty Day
macular edema secondary to inflammation (MESI)source ↗
◆Oral Presentationtabirafusp-tedPresentation
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted at AAO 2026 Retina Subspecialty Day
wet age-related macular degenerationsource ↗
▲Topline ReadoutZenkudaClinical Data
Kodiak announced topline results from Phase 3 DAYBREAK in wet AMD
wet age-related macular degenerationsource ↗
◆Topline ReadoutKSI-501Clinical Data
Topline results from DAYBREAK Phase 3 study of Zenkuda and KSI-501 in wet AMD
wet age-related macular degenerationsource ↗
▲Primary Endpoint Mettabirafusp-tedClinical Data
DAYBREAK met primary endpoint for tabirafusp-ted with non-inferior vision gains vs aflibercept at Year 1
wet age-related macular degenerationsource ↗
▲Primary Endpoint MetZenkudaClinical Data
DAYBREAK met primary endpoint for Zenkuda with non-inferior vision gains vs aflibercept at Year 1
wet age-related macular degenerationsource ↗
▲Topline Readouttabirafusp-tedClinical Data
Kodiak announced topline results from Phase 3 DAYBREAK in wet AMD
wet age-related macular degenerationsource ↗
▲Primary Endpoint Mettabirafusp-tedClinical Data
Tabirafusp-ted met vision primary endpoint in Phase 3 DAYBREAK trial in wAMD
wet age-related macular degeneration (wAMD)source ↗
▲Secondary Endpoint Datatabirafusp-tedClinical Data
Tabirafusp-ted met anatomical key secondary endpoint in DAYBREAK
wet age-related macular degeneration (wAMD)source ↗
▲Primary Endpoint MetZenkudaClinical Data
Zenkuda met primary endpoint in Phase 3 DAYBREAK trial in wAMD
wet age-related macular degeneration (wAMD)source ↗
▲Trial InitiationKSI-501Trial
First patients enrolled in Phase 3 ALTO study
Diabetic Macular Edemasource ↗
▲First Patient DosedKSI-501Trial
First patients enrolled in Phase 3 ALTO trial of KSI-501 in DME
diabetic macular edemasource ↗
▲Trial InitiationKSI-501Trial
Initiated patient enrollment in Phase 3 ALTO study of KSI-501
Diabetic Macular Edemasource ↗
◆Topline ReadoutKSI-501Clinical Data
Topline data readout for KSI-501 in retinal vascular diseases
retinal vascular diseasessource ↗
◆Topline ReadoutZenkudaClinical Data
Topline data expected from DAYBREAK Phase 3 study for Zenkuda and KSI-501
Wet AMDsource ↗
▲Enrollment CompleteKSI-101Trial
Enrollment completed for first 300-patient cohort in PEAK supporting Pivotal Analysis 1
Macular Edema Secondary to Inflammationsource ↗
◆Oral PresentationPresentation
Kodiak Sciences to present at 2026 Jefferies Global Healthcare Conference
▲Enrollment CompleteKSI-101Trial
Completed enrollment of first 300-patient cohort in PEAK supporting Pivotal Analysis 1
Macular Edema Secondary to Inflammationsource ↗
▲Enrollment CompleteZenkudaTrial
Enrollment completed in DAYBREAK Phase 3 study of Zenkuda and KSI-501 in wet AMD
neovascular age-related macular degeneration (wet AMD)source ↗
▲Enrollment CompleteKSI-501Trial
Enrollment completed in DAYBREAK Phase 3 study of KSI-501 and Zenkuda in wet AMD
neovascular age-related macular degeneration (wet AMD)source ↗
◆Poster PresentationKSI-101Presentation
Poster presentation of KSI-101 Phase 1b APEX study results at ARVO
Macular Edema Secondary to Inflammation (MESI)source ↗
◆Poster PresentationKSI-101Presentation
Poster presentation of KSI-101 Asian cohort results at ARVO
Macular Edema Secondary to Inflammation (MESI)source ↗
◆Poster PresentationKSI-102Presentation
Poster presentation of KSI-102 preclinical data at ARVO
Ocular Inflammatory Diseasessource ↗
◆Poster PresentationPresentation
Poster presentation of IL-6/Complement and VEGF/Complement dual inhibitors for GA at ARVO
Geographic Atrophysource ↗
◆Oral PresentationKSI-101Presentation
Presentation of KSI-101 Phase 1b APEX study results at AUS Meeting
Macular Edema Secondary to Inflammation (MESI)source ↗
◆Topline ReadoutTarcocimabFiledClinical Data
Topline data expected in 2Q 2026
wet age-related macular degenerationsource ↗
▲Enrollment CompleteZenkudaTrial
Completed enrollment in Phase 3 DAYBREAK study of Zenkuda and KSI-501 in wet AMD
neovascular age-related macular degeneration (wet AMD)source ↗
▲Enrollment CompleteKSI-501Trial
Completed enrollment in Phase 3 DAYBREAK study of KSI-501 in wet AMD
neovascular age-related macular degeneration (wet AMD)source ↗
▲Topline ReadoutZenkudaClinical Data
Positive topline results in GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy
diabetic retinopathysource ↗
▲Primary Endpoint MetZenkudaClinical Data
GLOW2 met primary endpoint of ≥2-step DRSS improvement at Week 48
diabetic retinopathysource ↗
◆Oral PresentationKSI-101Presentation
Week 24 data from APEX to be presented at Angiogenesis, Exudation, and Degeneration 2026 Annual Meeting
macular edema secondary to inflammation (MESI)source ↗
▲Topline ReadoutKSI-101Clinical Data
Final Phase 1b APEX data for KSI-101 in MESI presented at Angiogenesis meeting
macular edema secondary to inflammation (MESI)source ↗
◆Enrollment UpdateKSI-101Trial
PINNACLE Phase 3 study actively enrolling
macular edema secondary to inflammationsource ↗
◆Topline ReadoutTarcocimabFiledClinical Data
Topline data readout for tarcocimab in retinal vascular diseases
retinal vascular diseasessource ↗
◆Primary CompletionTarcocimabFiledTrial
Primary endpoint visits expected to complete
diabetic retinopathysource ↗
◆Topline ReadoutTarcocimabFiledClinical Data
Topline data expected in 1Q 2026
diabetic retinopathysource ↗
▼Equity OfferingCorporate
Closing of $184 million public offering of common stock including full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of upsized public offering of common stock at $23.00 per share
▼Equity OfferingCorporate
Proposed underwritten public offering of 6,000,000 shares of common stock
▼Equity OfferingCorporate
Completed follow-on equity offering of 8 million shares at $23.00 per share
Past FDA Catalysts and PDUFA Decisions
How KOD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-10 | Zenkuda (tarcocimab tedromer) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 23%
Small Cap(rank 152 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tarcocimab tedromer Monoclonal antibodyNCT06556368 | Wet Age-related Macular Degeneration | Phase 3 | ACTIVE NOT_RECRUITING | 675 | Aug 1, 2027 | ||||||
| KSI-101 Small moleculeNCT06990399 | Macular Edema Secondary to Inflammation | Phase 3 | RECRUITING | 900 | Nov 1, 2027 | ||||||
| Tabirafusp tedromer Small moleculeNCT07734844 | Diabetic Macular Edema (DME) | Phase 3 | RECRUITING | 910 | Sep 1, 2029 | ||||||
| Tarcocimab Monoclonal antibodyCompletedNCT06270836 | Diabetic Retinopathy | Phase 3 | COMPLETED | 255 | Feb 13, 2026 | ||||||
| KSI-301 Small moleculeCompletedNCT04592419 | Macular Edema | Phase 3 | COMPLETED | 568 | Jan 19, 2023 | ||||||
| KSI-301 Small moleculeCompletedNCT04964089 | Wet Age-related Macular Degeneration | Phase 3 | COMPLETED | 557 | Apr 6, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every KOD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Zenkuda, tabirafusp-ted | wet age-related macular degeneration | Phase 3 | 2026-10-07 | the study met its primary endpoint for each investigational treatment, with both Zenkuda and tabirafusp-ted demonstrating non-inferior vision gains compared with aflibercept at Year 1Read More | Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LPDirector, 10% Owner | Buy | 619 1,668,448 held | $84.24 | 09/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KOD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 3.9 % (-11.4 %) | 776.05 M | 19.92 M |
KOD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KOD ranks across every disease it competes in
Competitive Position is a premium feature
See how KOD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKOD News
KODKodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
Kodiak Sciences Inc. announced that it will present clinical data for its late-stage programs at the AAO 2026. Key presentations include the Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet AMD, as well as data from the GLOW2 and APEX studies. The DAYBREAK study met its primary endpoint, showing promising results compared to aflibercept.
Read more →KOD▲ +178%on this news· ran to +204% by day 3
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
Zenkuda (tarcocimab tedromer) successfully met its primary endpoint in the pivotal DAYBREAK trial for wet age-related macular degeneration (wAMD), showing significant vision improvements and rapid retinal drying. Notably, 54% of patients were able to maintain a 6-month dosing interval. This positions Zenkuda as a potential first-line treatment option.
Read more →KOD▲ +178%on this news· ran to +204% by day 3shared move
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences Inc. will present topline results from its DAYBREAK Phase 3 study on September 28, 2026. The study evaluates Zenkuda and KSI-501 for treating wet age-related macular degeneration. The webcast will provide insights into the efficacy of these treatments, which target a significant market in retinal diseases.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
Kodiak Sciences reported its second quarter 2026 financial results, highlighting significant progress in its late-stage clinical portfolio. The company anticipates topline data from three Phase 3 studies by the end of the year, including DAYBREAK and PEAK studies. Despite a net loss of $65.6 million, Kodiak's cash reserves are expected to sustain operations into 2027.
Read more →KODKodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences has enrolled the first patients in the global Phase 3 ALTO trial for KSI-501, aimed at treating diabetic macular edema (DME). This trial will compare the efficacy of KSI-501, a bispecific therapy targeting IL-6 and VEGF, against aflibercept. The study seeks to demonstrate improved disease control and visual outcomes for patients with DME, addressing limitations of existing treatments.
Read more →KODKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
Kodiak Sciences has completed enrollment of 300 patients in the first pivotal cohort of its Phase 3 PEAK trial for KSI-101, targeting macular edema secondary to inflammation. The company anticipates releasing topline data in December 2026. KSI-101 aims to provide a safer and more effective treatment option for patients at risk of vision loss due to MESI.
Read more →KODKodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
Kodiak Sciences Inc. will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. CEO Victor Perlroth, M.D., will lead the presentation, showcasing the company's commitment to developing transformative retinal therapeutics. A live webcast will be available for those unable to attend in person.
Read more →KODKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
Kodiak Sciences reported positive Phase 3 results for Zenkuda, demonstrating significant efficacy in diabetic retinopathy. The company is advancing its late-stage pipeline with multiple readouts expected in 2026, including studies for wet AMD and macular edema. Despite a net loss of $58.2 million in Q1 2026, Kodiak's cash position supports operations into 2027.
Read more →KODKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Kodiak Sciences announced it will present clinical data for KSI-101 at the upcoming American Uveitis Society and ARVO meetings. The results from a tertiary care cohort are consistent with previous studies, indicating the drug's potential across diverse patient populations. The company is advancing its pipeline, including KSI-101, KSI-102, and KSI-103, aimed at treating retinal diseases.
Read more →KOD▲ +12.3%on this news
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Kodiak Sciences reported positive Phase 3 topline results for Zenkuda in diabetic retinopathy and highlighted advancements in its pipeline programs. The company completed enrollment in the Phase 3 DAYBREAK study for wet AMD and continues to develop KSI-101 and other candidates. Despite a net loss increase, Kodiak's cash position supports its operations into 2027.
Read more →KOD▲ +74.8%on this newsshared move
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Kodiak Sciences announced positive topline results from the GLOW2 Phase 3 study, showing Zenkuda's superiority over sham in treating diabetic retinopathy. The study included a broader patient population and demonstrated a significant improvement in DRSS scores. Zenkuda was well-tolerated, with no serious ocular adverse events reported, supporting its potential as a long-lasting treatment option.
Read more →KOD▼ -6.9%on this news
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
Kodiak Sciences announced the presentation of final results from the Phase 1b APEX study for KSI-101 at the Angiogenesis 2026 meeting. The data indicate significant visual and anatomical improvements in patients with macular edema secondary to inflammation. These findings bolster confidence in KSI-101's potential as a leading therapy for MESI, with ongoing Phase 3 studies actively enrolling participants.
Read more →KOD▲ +8.1%on this news
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
Kodiak Sciences Inc. has announced that its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will highlight the company's precommercial efforts and its portfolio of late-stage clinical programs targeting retinal diseases. Kodiak is aiming to address leading causes of blindness with its innovative therapeutics, including candidates in Phase 3 studies. Live webcasting of the event will be available on Kodiak's website.
Read more →KODKodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
Kodiak Sciences Inc. has successfully closed a public offering of 8 million common shares, raising approximately $184 million. This amount includes shares sold through the underwriters' full exercise of their additional purchase option. The funds will strengthen Kodiak's financial position as the company progresses through critical Phase 3 topline readouts for its late-stage clinical assets. The offering was conducted through a previously filed registration statement with the SEC.
Read more →KODKodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
Kodiak Sciences, a biotechnology company focused on retina therapies, has announced the pricing of an upsized public offering of approximately 6.96 million shares at $23.00 per share. This offering is anticipated to raise around $160 million before expenses. The transaction is subject to customary closing conditions and is expected to close on or about December 18, 2025. Additionally, Kodiak has granted underwriters a 30-day option to purchase additional shares.
Read more →KODKodiak Sciences Announces Proposed Public Offering of Common Stock
Kodiak Sciences Inc. has announced a proposed public offering of 6 million shares of common stock, with an option for underwriters to purchase an additional 900,000 shares. The offering is subject to market conditions and is intended to support the company's development of transformative retinal therapeutics. The shares will be sold under a previously filed shelf registration statement.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Kodiak Sciences reported strong business highlights and financial results for Q3 2025, showcasing positive momentum in its late-stage programs. The company anticipates continued progress into 2026 with multiple Phase 3 data readouts and a planned BLA filing. Despite a net loss increase and rising R&D expenses, the firm remains optimistic about its pipeline advancements.
Read more →KOD▼ -6.8%on this newsshared move
Kodiak Sciences to Present at Upcoming Investor Conferences
Kodiak Sciences Inc. will present at upcoming investor conferences, highlighting its commitment to developing innovative retinal therapeutics. CEO Victor Perlroth will lead the presentations, which will be available via live webcast. The company is advancing three late-stage clinical programs targeting retinal vascular diseases and macular edema.
Read more →KODFollow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Kodiak Sciences has reported promising follow-up data from the APEX study of KSI-101, an investigational therapy for macular edema secondary to inflammation (MESI). The data indicates that over 90% of patients achieved absence of retinal fluid by week 20, with significant improvements in visual acuity. The company aims to advance KSI-101 into Phase 3 studies, potentially establishing it as a cornerstone therapy for MESI.
Read more →About Kodiak Sciences Inc
Headquarters1250 PAGE MILL RD, PALO ALTO, CA, 94304
BIOPHARMAWATCH ELITE PLUS
Trade the next KOD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime